Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

All applications must fall within Alzheimer’s Research UK’s remit which covers biomedical research in Alzheimer’s disease and other dementias. Alzheimer’s Research UK funds research into treatment, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

These weight loss medications, administered via injections, work by mimicking a hormone called GLP-1, which helps regulate appetite and blood sugar levels.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Each disease brain tour guides you through four levels of content, allowing you to: 1. See how regions of the brain are affected by different types of dementia. 2. Look closely at brain cells and ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...